Group 1 - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2] - The partnership began in April 2025, focusing on deep collaboration in drug discovery and development by integrating AI technology with traditional drug development advantages [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle clinical trial application support and subsequent clinical trial implementation [1] Group 2 - Insilico Medicine's Pharma.AI platform has efficiently advanced early-stage research, producing preclinical data that meets the PCC nomination standards set by both companies [2] - The rapid achievement of the PCC nomination demonstrates the potential of AI-driven innovation in early drug development, particularly in addressing unmet clinical needs [2][3] - Haizheng Pharmaceutical expressed strong impressions regarding the efficiency and quality of the project, highlighting the integration of traditional pharmaceutical experience with cutting-edge AI technology as a key step in their digital transformation [3]